PlateletBio
Financing Rounds
- Series B
- Exit
Round Led or Co-led By SymBiosis
Round Led or Co-led By SymBiosis
Inspired by the biological function and versatility of platelets, PlateletBio is pioneering the next generation of safer, more effective cell therapies. Its cell therapy platform produces “platelet-like cells” (PLCs) capable of performing vital biological functions and able to be genetically engineered into multiple allogeneic cell therapies. The Company is focused on advancing a diverse pipeline of next-generation cellular therapies for applications in autoimmune diseases, hematology, and inflammation.
Modality
- Cell Therapy
Indication
- Immunology & Inflammation
Development Status
- Pre-Clinical